Article Versions Notes

Thomas QD, Girard N, Bosquet L, Cavaillon S, Filleron T, Eltaief S, Chouaid C, Lena H, Debieuvre D, Perol M, et al. Optimizing Treatment Strategies for Egfr-Mutated Non-Small-Cell Lung Cancer Treated with Osimertinib: Real-World Outcomes and Insights. Cancers. 2024; 16(21):3563. https://doi.org/10.3390/cancers16213563

Thomas, Quentin Dominique, Nicolas Girard, Lise Bosquet, Sarah Cavaillon, Thomas Filleron, Siham Eltaief, Christos Chouaid, Hervé Lena, Didier Debieuvre, Maurice Perol, and et al. 2024. "Optimizing Treatment Strategies for Egfr-Mutated Non-Small-Cell Lung Cancer Treated with Osimertinib: Real-World Outcomes and Insights" Cancers 16, no. 21: 3563. https://doi.org/10.3390/cancers16213563

Thomas, Q. D., Girard, N., Bosquet, L., Cavaillon, S., Filleron, T., Eltaief, S., Chouaid, C., Lena, H., Debieuvre, D., Perol, M., & Quantin, X. (2024). Optimizing Treatment Strategies for Egfr-Mutated Non-Small-Cell Lung Cancer Treated with Osimertinib: Real-World Outcomes and Insights. Cancers, 16(21), 3563. https://doi.org/10.3390/cancers16213563